Old Web
English
Sign In
Acemap
>
authorDetail
>
Alex Kouassi
Alex Kouassi
Merck & Co.
Psychology
Placebo
Asenapine
Tolerability
Psychiatry
5
Papers
97
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
2016
Journal of Clinical Psychopharmacology
Azmi F. Nasser
David C. Henderson
Maurizio Fava
Paul J Fudala
Philip Twumasi-Ankrah
Alex Kouassi
Christian Heidbreder
Show All
Source
Cite
Save
Citations (23)
Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
2016
Schizophrenia Research
John J. Isitt
Vijay R Nadipelli
Alex Kouassi
Maurizio Fava
Christian Heidbreder
Show All
Source
Cite
Save
Citations (14)
Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia
2012
Journal of Clinical Psychopharmacology
Robert W. Buchanan
John Panagides
Jun Zhao
Phillip Phiri
Wil den Hollander
Xianwei Ha
Alex Kouassi
Larry Alphs
Nina R. Schooler
Armin Szegedi
Pilar Cazorla
Show All
Source
Cite
Save
Citations (47)
PW01-28 - Asenapine as adjunctive treatment for bipolar mania: a placebo-controlled 12-week study and 40-week extension
2010
European Psychiatry
Joseph R. Calabrese
L. Stet
H. Kotari
J Zhao
Alex Kouassi
Armin Szegedi
John Panagides
Show All
Source
Cite
Save
Citations (9)
ASENAPINE VERSUS OLANZAPINE IN PATIENTS WITH PREDOMINANT PERSISTENT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
2008
Schizophrenia Research
Robert Buchanan
Pilar Cazorla
John Panagides
Alex Kouassi
Armin Szegedi
Show All
Source
Cite
Save
Citations (4)
1